Substituted 2-arylbenzothiazoles as kinase inhibitors: Hit-to-lead optimization

Bioorganic and Medicinal Chemistry

Volumn 17, Issue 18, 2009, Pages 6728-6737

  Tasler, Stefan ^a   Müller, Oliver ^a   Wieber, Tanja ^a   Herz, Thomas ^a   Pegoraro, Stefano ^a   Saeb, Wael ^a   Lang, Martin ^a   Krauss, Rolf ^a   Totzke, Frank ^b   Zirrgiebel, Ute ^b   Ehlert, Jan E ^b   Kubbutat, Michael H G ^b   Schächtele, Christoph ^b  

^a 4SC AG   (Germany)

^b PROQINASE GMBH   (Germany)

Author keywords

Cancer; Multi target approach; Protein kinase; vHTS

Indexed keywords

ANGIOPOIETIN RECEPTOR; AURORA A KINASE; AURORA B KINASE; BENZOTHIAZOLE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ARTICLE; CELL PROLIFERATION; CELL STRAIN HCT116; CELL SURVIVAL; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; ENZYME INHIBITOR INTERACTION; HUMAN; HUMAN CELL; IC 50; METASTASIS POTENTIAL; PHOSPHORYLATION; PROCESS OPTIMIZATION; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; BENZOTHIAZOLES; CELL LINE, TUMOR; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 69249091852     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.07.047     Document Type: Article

References (51)

1. Tasler S., Müller O., Wieber T., Herz T., Krauss R., Totzke F., Kubbutat M.H.G., and Schächtele C. Bioorg. Med. Chem. Lett. 19 (2009) 1349
2. Harrington E.A., Bebbington D., Moore J., Rasmussen R.K., Ajose-Adeogun A.O., Nakayama T., Graham J.A., Demur C., Hercend T., Diu-Hercend A., Su M., Golec J.M.C., and Miller K.M. Nature Med. 10 (2004) 262
3. Shchemelinin I., Sefc L., and Necas E. Folia Biolog. 52 (2006) 137
4. Blume-Jensen P., and Hunter T. Nature 411 (2001) 355
5. Muhsin M., Graham J., and Kirkpatrick P. Nat. Rev. Drug Disc. 2 (2003) 515
6. Dancey J., and Sausville E.A. Nat. Rev. Drug Disc. 2 (2003) 296
7. Normanno N., Bianco C., Strizzi L., Mancino M., Maiello M.R., De Luca A., Caponigro F., and Salomon D.S. Curr. Drug Targets 6 (2005) 243
8. Albanell J., and Gascon P. Curr. Drug Targets 6 (2005) 259
9. Blagden S., and de Bono J. Curr. Drug Targets 6 (2005) 325
10. Liao J.J.-L. J. Med. Chem. 50 (2007) 409
11. Stadler W.M. J. Clin. Oncol. 24 (2006) 4
12. Daub H., Specht K., and Ullrich A. Nat. Rev. Drug Disc. 3 (2004) 1001
13. Bridges A.J. Chem. Rev. 101 (2001) 2541
14. Underiner T.L., Ruggeri B., and Gingrich D.E. Curr. Med. Chem. 11 (2004) 731
15. For a list of kinases for which binding assays have been established, see www.proqinase.com; Sachsenmaier, C.; Schaechtele, C. BioTechniques 2002, 33, 101.
16. Barker A.J., Gibson K.H., Grundy W., Godfrey A.A., Barlow J.J., Healy M.P., Woodburn J.R., Ashton S.E., Curry B.J., Scarlett L., Henthorn L., and Richards L. Bioorg. Med. Chem. Lett. 11 (2001) 1911
17. Pandey A., Volkots D.L., Seroogy J.M., Rose J.W., Yu J.-C., Lambing J.L., Hutchaleelaha A., Hollenbach S.J., Abe K., Giese N.A., and Scarborough R.M. J. Med. Chem. 45 (2002) 3772
18. Berger D., Dutia M., Powell D., Wissner A., DeMorin F., Raifeld Y., Weber J., and Boschelli F. Bioorg. Med. Chem. Lett. 12 (2002) 2989
19. Barge, A. W.O. Patent 2004/043472 A1, 2004; Chem. Abstr. 2004, 141, 1220
20. Plé, P. W.O. Patent 2004/041829 A1, 2004; Chem. Abstr. 2004, 140, 423698.
21. Meyer J.F., and Wagner E.C. J. Org. Chem. 8 (1943) 239
22. Alexandre F.R., Berecibar A., and Besson T. Tetrahedron Lett. 43 (2002) 3911
23. Kolloff H.G., Hunter J.H., Woodruff E.H., and Moffett R.B. J. Am. Chem. Soc. 70 (1948) 3862
24. For similar reaction conditions (HCl, i-PrOH, Δ), see:. Plé P.A., Green T.P., Hennequin L.F., Curwen J., Fennell M., Allen J., Lambert-van der Brempt C., and Costello G. J. Med. Chem. 47 (2004) 871
25. Kubo K., Shimizu T., Ohyama S.-i., Murooka H., Iwai A., Nakamaru K., Hasegawa K., Kobayashi Y., Takahashi N., Takahashi K., Kato S., Izawa T., and Isoe T. J. Med. Chem. 48 (2005) 1359
26. Kashiyama E., Hutchinson I., Chua M.-S., Stinson S.F., Phillips L.R., Kaur G., Sausville E.A., Bradshaw T.D., Westwell A.D., and Stevens M.F.G. J. Med. Chem. 42 (1999) 4172
27. Hutchinson I., Chua M.-S., Browne H.L., Trapani V., Bradshaw T.D., Westwell A.D., and Stevens M.F.G. J. Med. Chem. 44 (2001) 1446
28. Phoon C.W., Ng P.Y., Ting A.E., Yeo S.L., and Sim M.M. Bioorg. Med. Chem. Lett. 11 (2001) 1647 For additional literature on 2′-arylbenzothiazole syntheses, see ref. S1, Supplementary data
29. Barbacci E.G., Pustilnik L.R., Rossi A.M.K., Emerson E., Miller P.E., Boscoe B.P., Cox E.D., Iwata K.K., Jani J.P., Provoncha K., Kath J.C., Liu Z., and Moyer J.D. Cancer Res. 63 (2003) 4450 Additionally, a sequence alignment was performed and compared with the pocket as deduced from the crystal structure of Iressa, PDB code 2ITY
30. Aronov A.M., McClain B., Moody C.S., and Murcko M.A. J. Med. Chem. 51 (2008) 1214
31. Heron N.M., Anderson M., Blowers D.P., Breed J., Eden J.M., Green S., Hill G.B., Johnson T., Jung F.H., McMiken H.H.J., Mortlock A.A., Pannifer A.D., Pauptit R.A., Pink J., Roberts N.J., and Rowsell S. Bioorg. Med. Chem. Lett. 16 (2006) 1320
32. Hennequin L.F., Stokes E.S.E., Thomas A.P., Johnstone C., Plé P.A., Ogilvie D.J., Dukes M., Wedge S.R., Kendrew J., and Curwen J.O. J. Med. Chem. 45 (2002) 1300
33. Jung F.H., Pasquet G., Lambert-van der Brempt C., Lohmann J.-J.M., Warin N., Renaud F., Germain H., De Savi C., Roberts N., Johnson T., Dousson C., Hill G.B., Mortlock A.A., Heron N., Wilkinson R.W., Wedge S.R., Heaton S.P., Odedra R., Keen N.J., Green S., Brown E., Thompson K., and Brightwell S. J. Med. Chem. 49 (2006) 955
34. Hennequin L.F., Allen J., Breed J., Curwen J., Fennell M., Green T.P., Lambert-van der Brempt C., Morgentin R., Norman R.A., Olivier A., Otterbein L., Plé P.A., Warin N., and Costello G. J. Med. Chem. 49 (2006) 6465
35. Knight, Z. A.; Shokat, K. M. Chem. Biol. 2005, 12, 621; cf. also. Schäfer M., and Egner U. Anti-Inflamm. Anti-Allergy Agents Med. Chem. 6 (2007) 5
36. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., Klevernic I., Arthur J.S.C., Alessi D.R., and Cohen P. Biochem. J. 408 (2007) 297
37. Diller D.J., and Li R. J. Med. Chem. 46 (2003) 4638
38. Copeland R.A., Pompliano D.L., and Meek T.D. Nat. Rev. Drug Disc. 5 (2006) 730
39. La Porta C.A.M. Curr. Drug Targets 5 (2004) 347
40. Sun L., Liang C., Shirazian S., Zhou Y., Miller T., Cui J., Fukuda J.Y., Chu J.-Y., Nematalla A., Wang X., Chen H., Sistla A., Luu T.C., Tang F., Wei J., and Tang C. J. Med. Chem. 46 (2003) 1116
41. Faivre S., Demetri G., Sargent W., and Raymond E. Nat. Rev. Drug Disc. 6 (2007) 734
42. Stamos J., Sliwkowski M.X., and Eigenbrot C. J. Biol. Chem. 277 (2002) 46265
43. Dowell J., Minna J.D., and Kirkpatrick P. Nat. Rev. Drug Disc. 4 (2005) S14
44. Gunby R.H., Ahmed S., Sottocornola R., Gasser M., Redaelli S., Mologni L., Tartari C.J., Belloni V., Gambacorti-Passerini C., and Scapozza L. J. Med. Chem. 49 (2006) 5759
45. Blencke S., Zech B., Engkvist O., Greff Z., Örfi L., Horvath Z., Keri G., Ullrich A., and Daub H. Chem. Biol. 11 (2004) 691
46. Böhmer F.D., Karagyozov L., Uecker A., Serve H., Botzki A., Mahboobi S., and Dove S. J. Biol. Chem. 278 (2003) 5148
47. Liu Y., Bishop A., Witucki L., Kraybill B., Shimizu E., Tsien J., Ubersax J., Blethrow J., Morgan D.O., and Shokat K.M. Chem. Biol. 6 (1999) 671
48. Ostrander J.H., Daniel A.R., Lofgren K., Kleer C.G., and Lange C.A. Cancer Res. 67 (2007) 4199
49. Linger R.M.A., Keating A.K., Earp H.S., and Graham D.K. Adv. Cancer Res. 100 (2008) 35
50. Sun Y. Mol. Carcinog. 45 (2006) 409
51. Macmillan J.C., Hudson J.W., Bull S., Dennis J.W., and Swallow C.J. Ann. Surg. Oncol. 8 (2001) 729